Preclinical work and a Phase 1 evaluation of OcuRing-K reported reductions in post-cataract pain and inflammation with lower total drug exposure than standard drop regimens, supported by sustained intraocular ketorolac levels. The company also highlights the inefficiency of topical delivery, with typical post-op drops delivering under 5% of drug into the eye, a gap OcuRing-K aims to address with a single intraoperative depot.
The core development is straightforward: after taking a majority stake in LayerBio, PainReform has completed a joint assessment and initiated an advancement plan to move OcuRing-K into a U.S.-based Phase 2 trial. OcuRing-K is an erodible, intraoperatively placed, sustained-release ocular therapy designed to deliver ketorolac locally and consistently, replacing multi-week post-op NSAID and steroid drops with a drop-less approach. The program now sits inside PainReform’s pharmaceutical portfolio, with the U.S. as the lead regulatory and commercial pathway.
The strategic logic is to ride the growing preference for drop-less cataract recovery while differentiating on mechanism. Most marketed or near-market drop-less options in cataract surgery have centered on steroids delivered intracanalicularly or intracamerally. A ketorolac-based, sustained-release modality gives PainReform a route to pain control and inflammation mitigation without steroid exposures, potentially sidestepping steroid-associated IOP spikes and aligning with surgeons who already pair NSAIDs with intracameral antibiotics. It also leverages a known molecule, suggesting a 505(b)(2)-style regulatory path that could compress timelines if safety and efficacy are clean. The tension is clear: post-op management often employs both an NSAID and a steroid, so a single-agent NSAID implant must either demonstrate non-inferiority to combination drop regimens or show that it can be paired operationally and economically with a steroid strategy without eroding its “single-touch” value proposition.
For sites and surgeons, an intraoperative, erodible insert could simplify postoperative workflows, reduce drop counseling and adherence monitoring, and lower contamination risk. Operationally, it adds a placement step in the OR or ASC, demands inventory and sterility controls typical of drug-device combo products, and shifts follow-up away from adherence toward outcome verification. For sponsors and CROs, the cataract setting offers high-volume, rapid enrollment with standardized assessments, but trials must control for surgeon variability and consistently capture pain scores, rescue medication use, and SUN cell/flare grading. Regulators will view this as a combination product with a pharmacologic primary mode of action, raising CMC and device-performance expectations around release kinetics, erosion profile, and ocular safety. Reimbursement is the other hinge: in the ASC and HOPD environment, many perioperative therapies are packaged; meaningful adoption often requires a path to separate payment, at least initially, or a clear total-cost-of-care case that fits within bundled payments.
What to watch next is Phase 2 design choices. A randomized comparison against standard-of-care drops, durability of effect through the critical first two to four weeks, and rates of rescue therapy will set the regulatory narrative. Safety will be scrutinized for corneal and anterior segment adverse events historically associated with topical NSAIDs, even if overall exposure is lower. Manufacturing scale-up for a precise, reproducible erosion profile will be a gating factor. Strategically, a follow-on program that layers a steroid onto the same platform—or a clear clinical rationale for NSAID-only control—will determine commercial positioning. The broader signal is that cataract perioperative care remains in play: if OcuRing-K can demonstrate consistent outcomes with minimal OR friction and a viable reimbursement pathway, it could accelerate the shift from patient-managed drops to surgeon-controlled, single-event therapeutics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
